Fresenius Lifts Sales Outlook as Revamp Gains Momentum (1)

Fresenius SE lifted its full-year sales outlook after a strong performance by the German health-care group’s hospitals and Kabi, its biopharma and med tech unit.

Organic revenue growth is expected to increase 5% to 7%, up from the previous range of 4% to 6%, the company said Wednesday.

Fresenius shares rose nearly 2% in early trading in Frankfurt, bringing this year’s gain to 25%.

Chief Executive Officer Michael Sen, who took the helm in 2022, has streamlined the company’s once-sprawling portfolio and is trying to drive profit by focusing on two units — Kabi, which makes biosimilars, medical devices ...